Navigation Links
ULURU Inc. Announces Conference Call to Discuss Financial Results for the Second Quarter Ended June 30, 2009 and to Provide a Business Update

Addison, TEXAS, Aug. 5 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced that it has scheduled a conference call to discuss the second quarter ended June 30, 2009 financial results and provide a general business update on Monday, August 17, 2009 at 9:00 a.m. Eastern Time.

To participate in the conference call please dial (800) 357-0498, for international callers dial (850) 429-1388 (access code 23453#) five to ten minutes prior to the initiation of the teleconference. If you are unable to listen to the live broadcast, a replay of the call will be available starting on August 17, 2009 two hours following the end of the call until August 24, 2009 at 11:59 p.m. Eastern Time. For the U.S. replay, please dial (866) 415-9493 for international callers dial (585) 419-6446 (access code 23453#).

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers with improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For more information about ULURU Inc., please visit For more information about Altrazeal(TM), please visit

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat E. Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145

Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence at the American Podiatric Medical Association (APMA) Annual Scientific Meeting in Toronto, Canada
2. ULURU Inc. Announces Status of York Note Receivable
3. ULURU Inc. Reports First Quarter 2009 Financial Results
4. ULURU Inc. Announces Conference Call to Discuss Financial Results for the First Quarter Ended March 31, 2009 and to Provide a Business Update
5. ULURU Inc. Announces Altrazeal(TM) Clinical Experience Published in the International Wound Journal
6. ULURU Inc. Signs Offer Letter to Acquire York Pharma plc
7. ULURU Inc. (ULURU) Dealing Disclosure Requirements
8. ULURU Inc. Reports Financial Results for Fourth Quarter and Year Ended December 31, 2008
9. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update
10. ULURU Inc. Announces Appointment of Jeffrey A. Niezgoda, M.D., as Chairman of Scientific Advisory Board
11. ULURU Inc. Announces Senior Management Change
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... In honor of Pulmonary Hypertension ... and groups responsible for advancing care for pulmonary hypertension (PH) patients and helping ... public, will receive special recognition throughout 2016 as part of PHA’s 25th anniversary ...
(Date:11/25/2015)... ... 25, 2015 , ... Bcureful—a non-profit organization devoted to advancing ... public awareness of the disorder while helping to bring expert medical care and ... bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert H. ...
(Date:11/24/2015)... ... 2015 , ... Eric C. Seidel, DMD and Stephanie DeFilippo, ... revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses light energy ... dentist in Gettysburg, PA . From routine visits to cosmetic treatments, laser dentistry ...
(Date:11/24/2015)... CA (PRWEB) , ... November 24, 2015 , ... ... sizes, has launched their Black Friday sale a week early, offering 40% off ... to transform the intimate apparel industry through both mobile fit technology and the ...
(Date:11/24/2015)... ... ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, Dec. ... has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls under ... the device regulations. , Come up short in an inspection and the FDA can ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... 2015 Developmental, commercial, and regulatory/legal ... profitability of pharmaceutical products, says GBI Research ... regulatory/legal strategies all play a key role in boosting ... . --> Developmental, commercial, ... in boosting the profitability of pharmaceutical products, says ...
(Date:11/25/2015)... Research and Markets ( ) has ... Global Forecast to 2020" report to their offering. ... 37.21% of the total market share in 2014. The ... is projected to growth at the highest CAGR between ... to the fast growing water, industrial gas treatment, pharmaceutical, ...
Breaking Medicine Technology: